Nilutamide

Drug Profile

Nilutamide

Alternative Names: Anandron; Nilandron; RU 23908

Latest Information Update: 19 Jul 2016

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antiandrogens; Antineoplastics; Imidazolidines; Nitrobenzenes; Small molecules
  • Mechanism of Action Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer

Most Recent Events

  • 18 Jul 2016 Generic equivalent approved in US FDA for Prostate cancer (Metastatic disease)
  • 05 Apr 2013 No development reported - Clinical-Phase-Unknown for Prostate cancer (metastatic disease) in Japan (PO)
  • 05 Apr 2013 Discontinued - Phase-III for Prostate cancer (metastatic disease) in Peru (PO) before 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top